Their downregulation impairs antigen presentation to CD8+ and CD4+ T cells, promoting immune escape and compromising the effectiveness of T cell‐based immunotherapies, including checkpoint blockade, adoptive T cell therapy and cancer vaccines.28, 29. This evidence concerns the gene CD8A and cancer.